Data / Drug companies / Amneal Pharmaceuticals of New York LLC
Amneal Pharmaceuticals of New York LLC: 116 products in the FDA NDC directory, labeler code 0115
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Amneal Pharmaceuticals of New York LLC (labeler code 0115) lists 116 products in the FDA National Drug Code Directory, covering 38 finished drugs by generic name. By type: 116 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on April 1, 2025.
The request: Watch Amneal Pharmaceuticals of New York LLC (FDA labeler code 0115): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0115
- Products in commercial distribution
- 116
- Packages
- 209
- Finished drugs by generic name
- 38
- Prescription products
- 116
- Over the counter products
- 0
- Controlled substance products
- Schedule II 40, Schedule III 2
- Flagged as original packager
- 108 of 108 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- October 17, 1974
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 107 | 92.2% |
| Authorized generics (NDA) | 8 | 6.9% |
| New drug applications (NDA) | 1 | 0.9% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 116 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Methylphenidate hydrochloride | 9 | 39 |
| Lamotrigine | 8 | 51 |
| Oxymorphone hydrochloride | 7 | 9 |
| Dexmethylphenidate hydrochloride | 7 | 17 |
| Morphine sulfate | 7 | 31 |
| Alendronate sodium | 5 | 16 |
| Carvedilol phosphate | 4 | 10 |
| Acitretin | 4 | 8 |
| Hydrocortisone | 3 | 171 |
| Colestipol hydrochloride | 3 | 10 |
| Levalbuterol hydrochloride | 3 | 6 |
| Dipyridamole | 3 | 8 |
| Dantrolene sodium | 3 | 14 |
| Dextroamphetamine sulfate | 3 | 17 |
| Nitrofurantoin macrocrystals | 2 | 20 |
| Hydroxyzine pamoate | 2 | 30 |
| Colesevelam hydrochloride | 2 | 12 |
| Chloroquine phosphate | 2 | 4 |
| Digoxin | 2 | 33 |
| Fenofibric acid | 2 | 7 |
| Budesonide | 2 | 40 |
| Methyltestosterone | 2 | 2 |
| Apixaban | 2 | 8 |
| Pyridostigmine bromide | 2 | 20 |
| Sevelamer carbonate | 2 | 35 |
| Epinephrine | 2 | 32 |
| Ultramicrosize griseofulvin tablets | 2 | 1 |
| Terbutaline sulfate | 2 | 10 |
| Bupropion hydrochloride | 2 | 67 |
| Fenofibrate | 2 | 56 |
| Cyclobenzaprine hydrochloride | 2 | 61 |
| Cyproheptadine hydrochloride | 1 | 24 |
| Metaxalone | 1 | 38 |
| Fludrocortisone acetate | 1 | 15 |
| Rimantadine hydrochloride | 1 | 1 |
| Albendazole | 1 | 10 |
| Oxycodone hydrochloride | 1 | 36 |
| Tamsulosin hydrochloride | 1 | 38 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule, extended release | 29 | 25% |
| Tablet | 28 | 24.1% |
| Capsule | 19 | 16.4% |
| Tablet, film coated, extended release | 10 | 8.6% |
| Tablet, orally disintegrating | 8 | 6.9% |
| Tablet, film coated | 6 | 5.2% |
| Suspension | 4 | 3.4% |
| Solution | 3 | 2.6% |
| Capsule, delayed release | 2 | 1.7% |
| Powder, for suspension | 2 | 1.7% |
| Injection | 2 | 1.7% |
| Tablet, coated | 2 | 1.7% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Tamsulosin Hydrochloride | 0115-8211 | Capsule | Generic drugs (ANDA) | April 1, 2025 |
| Fenofibric Acid | 0115-1325 | Capsule, delayed release | Generic drugs (ANDA) | June 1, 2024 |
| Fenofibric Acid | 0115-1324 | Capsule, delayed release | Generic drugs (ANDA) | June 1, 2024 |
| Carvedilol Phosphate | 0115-1251 | Capsule, extended release | Generic drugs (ANDA) | January 1, 2024 |
| Carvedilol Phosphate | 0115-1250 | Capsule, extended release | Generic drugs (ANDA) | January 1, 2024 |
| Carvedilol Phosphate | 0115-1249 | Capsule, extended release | Generic drugs (ANDA) | January 1, 2024 |
| Carvedilol Phosphate | 0115-1248 | Capsule, extended release | Generic drugs (ANDA) | January 1, 2024 |
| Colesevelam hydrochloride | 0115-1864 | For suspension | Generic drugs (ANDA) | January 20, 2023 |
| Pyridostigmine Bromide | 0115-2134 | Tablet | Generic drugs (ANDA) | August 8, 2022 |
| Chloroquine Phosphate | 0115-7010 | Tablet | Generic drugs (ANDA) | May 10, 2022 |
| Chloroquine Phosphate | 0115-2790 | Tablet | Generic drugs (ANDA) | May 10, 2022 |
| Rimantadine Hydrochloride | 0115-1911 | Tablet, film coated | Generic drugs (ANDA) | November 16, 2021 |
| Dipyridamole | 0115-1072 | Tablet | Generic drugs (ANDA) | August 30, 2021 |
| Dipyridamole | 0115-1071 | Tablet | Generic drugs (ANDA) | August 30, 2021 |
| Dipyridamole | 0115-1070 | Tablet | Generic drugs (ANDA) | August 30, 2021 |
| Colestipol hydrochloride | 0115-5211 | Tablet, film coated | Generic drugs (ANDA) | August 17, 2021 |
| Sevelamer carbonate | 0115-1366 | Powder, for suspension | Generic drugs (ANDA) | November 20, 2020 |
| Sevelamer carbonate | 0115-1365 | Powder, for suspension | Generic drugs (ANDA) | November 20, 2020 |
| Cyclobenzaprine Hydrochloride | 0115-1437 | Capsule, extended release | Authorized generics (NDA) | March 1, 2019 |
| Cyclobenzaprine Hydrochloride | 0115-1436 | Capsule, extended release | Authorized generics (NDA) | March 1, 2019 |
| Lamotrigine | 0115-9942 | Tablet, orally disintegrating | Generic drugs (ANDA) | December 27, 2018 |
| Lamotrigine | 0115-9941 | Tablet, orally disintegrating | Generic drugs (ANDA) | December 27, 2018 |
| Lamotrigine | 0115-9940 | Tablet, orally disintegrating | Generic drugs (ANDA) | December 27, 2018 |
| Lamotrigine | 0115-9939 | Tablet, orally disintegrating | Generic drugs (ANDA) | December 27, 2018 |
| Morphine Sulfate | 0115-1479 | Capsule, extended release | Generic drugs (ANDA) | October 5, 2018 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.